Monitor for future equity grants under the new plan, which could signal management's confidence or need for retention. No immediate trading catalyst, the plan is standard governance and becomes effective in October 2026.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 8 $5.57entry
- T+1 · 5mo ago +1.62%α +1.91% · $5.66
- T+5 · 5mo ago −1.44%α −3.55% · $5.49
- T+20 · 4mo ago −9.34%α −10.97% · $5.05
- T+60 · 3mo ago −21.18%α −24.24% · $4.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lifecore Biomedical filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the 2026 Stock Incentive Plan and elected nine directors. The new plan authorizes 2.5 million new shares plus any forfeited shares from the prior 2019 plan, becoming effective October 16, 2026. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved the 2026 Stock Incentive Plan with 22,724,492 votes for, 392,825 against, and 13,086 abstentions.
- The 2026 Plan authorizes 2,500,000 new shares plus any forfeited shares from the 2019 Plan.
- The 2026 Plan becomes effective October 16, 2026, replacing the 2019 Stock Incentive Plan.
- All nine director nominees were elected, including two Series A Preferred directors elected solely by preferred stockholders.
- KPMG LLP was ratified as independent auditor for FY 2026 with 33,760,879 votes for.
- The say-on-pay advisory vote passed with 22,938,684 votes for.
Financial Impact
No financial impact; the 2026 Plan authorizes up to 2.5M new shares plus carryover from prior plan, but no immediate dilution or cash impact.
Risk Factors
- Potential future dilution from equity awards under the 2026 Plan.
- No material risk identified from this routine annual meeting filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001005286-26-000023 |
| Document: lfcr-20260604.htm | 0001005286-26-000023 |
| Document: 0001005286-26-000023-index-headers.html | 0001005286-26-000023 |
| Document: 0001005286-26-000023-index.html | 0001005286-26-000023 |
| Document: 0001005286-26-000023.txt | 0001005286-26-000023 |
Track record
20 reports on LFCR
6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +45.27% at T+60 after the Mar 26, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
- Nov 13, 20263d ago DEFM14A Neutral 6/10 Entry $6.42 Now $6.42 +0.00% settles Nov 17
- Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
- Nov 4, 202612d ago 8-K Bearish 6/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
- Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
- Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
- Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
- Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers